
Serious Adverse Events During Ruxolitinib Treatment Discontinuation in Patients With Myelofibrosis
Keywords: DLT; dose-limiting toxicity; ET; essential thrombocythemia; MF; myelofibrosis; MPN; myeloproliferative neoplasm; MTD; maximum tolerated dose; PMF; primary MF; PV; polycythemia vera;